Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults

Obesity Clinical Trial

— PHACO  

Official title:

Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02571959
• Other study ID #: IMEA 046
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: April 14, 2015
• Last updated: January 11, 2018
• Start date: July 24, 2015
• Est. completion date: June 16, 2017

Study information

• Verified date: January 2018
• Source: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration Determination of the pharmacokinetic parameters of amoxicillin / clavulanic acid obtained from plasmatic concentrations of intravenous injection (IV) and oral administrations. The criterion of evaluation allowing to answer our main objective corresponds to the parameters estimated by the pharmacokinetic model of the concentrations obtained from the data IV and by the pharmacokinetic model of the concentrations obtained from the oral data. The following pharmacokinetic parameters will be considered at every obese volunteer's for both molecules (amoxicillin and clavulanic acid) from the concentrations by pharmacokinetic analysis of population.

The main evaluation criteria are PK parameters of amoxicillin / clavulanic:

• Cl, systematic plasmatic clearance

• Vd, volume of distribution

• ASC 0-oo, area under the curve time - concentration

• T1/2, half-life time

• F, bioavailability after oral administration

• Ka, constant of speed of absorption

Description:

Main objective Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy voluntary obese after oral and intra venous administration

Secondary objectives

• Define dosage plans optimized with the antibiotic treatment to the obese subject

• Ensure an adequacy of the treatment with the related infection

• Formulate recommendations of dosage adaptations for a better individualization of treatments, by estimating several plans of doses by simulation to reach various PK/PD goals according to different theoretical MIC

Methodology

The pharmacokinetic analysis will be realized by approach of population allowing the estimation of the average parameters of amoxicillin and clavulanic acid as well as the interpersonal variability after an administration IV and an oral administration. Parameters's population and their variability will be estimated with the SAEM algorithm implemented in the software Monolix ( www.lixoft.eu ).

For the main objective, PK parameters PK of amoxicillin and clavulanic acid will be determined to day 1 and day 2. They will be described by means of indicators of position (average and median) and of dispersal (standard deviations, quartiles).

For secondary objectives, the profiles concentration/time of 1000 obese subjects will be determined by Monte Carlo method from PK parameters estimated at the balance by the model. For every feigned profile, the time during which the plasmatic concentration of amoxicillin and clavulanic acid is superior to a panel of theoretical MIC will be calculated by means of curves concentration - time determined for each of the subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 16, 2017
• Est. primary completion date: October 13, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Voluntary obese

• Body mass index upper to 30 kg/m2

• Age from 18 to 65 years

• Signed free and lit consent

• Possible participation according to the national file of the volunteers of the French Ministry of Health.

• Volunteers affiliated to the Social Security

Exclusion Criteria:

• Pregnancy

• Evolutionary pregnancy or feeding

• Allergy in ß-lactamines (nettle rash, oedema of Quincke)

• Digestive intolerance with amoxicillin / clavulanic acid

• Infection by the virus of the HIV ( positive Ac anti HIV)

• Infection by the virus of the hepatitis B ( positive Ag Hbs)

• Infection by the virus of the hepatitis C ( positive Ac anti VHC)

• Hepatic cirrhosis at the Child-Pugh C stage(stadium)

• Biological parameters:

• Polynucléaires neutrophiles 750 / mm3

• Haemoglobin 8g / dL

• Patellets 60 000 / mm3

• Creatinin clearance, according to MDRD, DFG 50 mL / min / 1,73m2

• ASAT or ALAT > 3 times the superior limit of the normal (LSN)

• Phosphatase alkaline > 3 LSN

• Total Bilirubine > 3 LSN

• Lipase > 3 LSN

• Factor V < 50 %

• Alcoholism chronicles (consumption superior to 30 g of alcohol a day, amount to 3 glasses of wine)

• Significant anomaly of the electrocardiogram, in particular QTc > 450 msec

• Subject susceptible not to respect the modalities of the study

• Drug addiction intra venous

• Any medical conditions which according to the judgment(sentence) of the investigator would may interfere with the moderate pharmacokinetic parameters

• People placed under legal protection

• Histories of bariatric surgery

Related Conditions & MeSH terms

• Obesity

Intervention

Drug:
• amoxicillin and clavulanic acid
Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
• amoxicillin and clavulanic acid
Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route

Locations

Country	Name	City	State
France	Hopital Ambroise Pare	Boulogne

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Systematic plasmatic clearance (Cl)		1 day
Secondary	Area under the curve time - concentration (AUC 0-oo)		1 day
Secondary	Half-life time (T1/2)		1 day
Secondary	Volume of distribution (Vd)		1 day
Secondary	Bioavailability after oral administration (F)		1 day
Secondary	Constant of speed of absorption (Ka)		1 day